EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Smith & Nephew plc (S1NN34) fair value: what the stock is really worth

As of Sep 30, 2026: fair value of Smith & Nephew plc BRL 22.38, price BRL 27.74, upside -19.3%, quality 68 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · BR · Home United Kingdom

SN Smith & Nephew plc logo Broad data Sep 23, 2026

Smith & Nephew plc

S1NN34 · SA

Overvalued / MonitorQuality is not strong enough to offset the price risk.

!Fair value R$22.38 · Overvalued (−19.3%)
✓Quality 68/100
✓Healthy Growth (revenue 3y +5.7 %/yr)
✓Solidly profitable · 10.1% net margin (TTM)
✓Moderate debt · generates free cash flow
✓1.4% dividend yield · Well covered
✓Ranks above peers (12/15)
!Moderate moat 52/100
!Insider activity 35/100
!Weak on dividend: 28 out of 100
Watch Smith & Nephew plc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

R$40.12 R$21.05 Fair Value R$22.38 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range R$21.05 – R$40.12 · fair‑value band R$13.46 – R$32.80 · the R$27.74 price screens above the R$22.38 fair value. Dashed = 300-day average. As of Sep 23, 2026.

Follow Smith & Nephew in your weekly email

Every Wednesday you see whether Smith & Nephew is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.

Show more

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Stock analysis

Smith & Nephew plc (S1NN34) currently trades at R$27.74, while our model-based Fair Value estimate is R$22.38, 19.3% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of R$28.98 per share, and 10 of the 26 models we run sit above the R$27.74 price.

Bear case: the Earnings-Based group reads lowest at R$8.44, and 16 of the 26 models stay below the price. Evidence for this calculation is high.

Scenario range: R$13.46 (bear) to R$32.80 (bull), the price of R$27.74 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Smith & Nephew plc reported revenue of $6.2B in FY2025 versus $5.2B in FY2021, a compound +4.3%/yr. Reported net income was $625M in FY2025, compounding +4.5%/yr from FY2021.

Key figures

Market cap R$66.6B (≈ $12.8B) · P/E ratio 18.7 · P/S ratio 1.90 · EPS (TTM) R$1.48 · Dividend yield 1.4% · Net margin 10.1% · Return on equity 11.8% · Return on assets (EBIT) 5.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 51 out of 100 (low confidence).

What moves the price

The share trades about 26% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −19%, S1NN34 screens richer than that median.

Fair Value models

Bear R$13.46 Fair Value R$22.38 Bull R$32.80
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (R$0.8235 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF R$17.24 R$29.11 R$46.73 75
Growth DCF R$17.76 R$28.48 R$43.54 74
Residual Income R$12.14 R$14.09 R$18.58 73
All 26 models by family
DCF Models
FCF DCF R$17.24 R$29.11 R$46.73 75
Owner Earnings R$14.85 R$25.52 R$41.34 71
5Y Revenue Exit R$13.10 R$23.07 R$35.49 68
5Y EBITDA Exit R$22.45 R$40.19 R$60.53 71
5Y P/E Exit R$16.73 R$29.73 R$43.02 67
10Y Revenue Exit R$13.87 R$23.22 R$35.17 63
10Y EBITDA Exit R$20.31 R$34.97 R$53.92 64
10Y P/E Exit R$16.70 R$27.79 R$40.81 60
Earnings-Based
Graham-Dodd R$10.53 R$29.38 R$38.62 62
Lynch FV R$5.91 R$8.44 R$10.97 58
PEG = 1.0 R$5.91 R$8.44 R$10.97 55
EPV R$8.68 R$11.15 R$13.31 71
Dividend Discount
Gordon GGM R$7.51 R$15.61 R$24.76 63
DDM Multi-Stage R$7.51 R$11.85 R$16.38 63
Multiples
P/E Multiple R$25.55 R$34.07 R$42.59 63
P/S Multiple R$19.75 R$26.33 R$32.91 58
P/B Multiple R$19.75 R$26.33 R$32.91 55
EV/EBIT R$18.96 R$27.32 R$35.68 65
EV/EBITDA R$29.44 R$41.30 R$53.15 67
EV/Revenue R$11.78 R$19.45 R$27.13 52
Asset-Based
NCAV (Graham) R$6.55 R$8.78 R$13.11 54
Growth DCF
Growth DCF R$17.76 R$28.48 R$43.54 74
Rev-Margin DCF R$13.10 R$23.27 R$34.67 68
Economic Profit
Residual Income R$12.14 R$14.09 R$18.58 73
ROIC Compounder R$8.68 R$11.15 R$13.50 69
Growth Earnings
Growth-Adj P/E R$20.29 R$28.98 R$37.67 65

Open the full fair value analysis →

Notify me when S1NN34 reaches fair value

Put S1NN34 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 68/100

Of which business quality 67 · Market factors (momentum, volatility) 36

Profitability 51
Margins and returns on capital today
Quality Growth 50
Are margins and returns improving?
Cashflow 72
Earnings quality: real cash, not paper profit
Fin. Strength 60
Balance sheet, leverage, solvency risk
Investment 88
Disciplined investing over empire-building
Low Volatility 93
Calm price path (market factor)
Momentum 19
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 96
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 75/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+6.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.7%
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+27.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+26.2%
Dividend (yield on the price)1.4%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 13%
2025 sits 145% above its own trend. The rate follows the median trend of the last 5 years, not that single year.

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−3.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+5.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −5.6% a year for the price and +2.8% for the forecasts.
Forecast 2026 (sales)+6.6%
Forecast 2027 (sales)+5.7%
Projected 2028 (sales)+5.2%
Projected 2029 (sales)+4.7%
Projected 2030 (sales)+4.3%

S1NN34 screens overvalued: fair value 19% below the price. Compare with Abbott Laboratories, →

Compare Smith & Nephew plc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 354 stocks

Beats the industry median on 12/15 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 68 · Top 25%
Fair Value upside +15.1% · Top 25%
Profitability
Return on equity (TTM) 11.8% · Top 25%
Return on assets 5.3% · Top 25%
Net margin (TTM) 10.1% · Above median
Operating margin (TTM) 14.0% · Above median
Growth and dividend
Revenue growth 7.4% · Above median
Dividend yield (TTM) 1.4% · Below median
Balance sheet
Debt / equity 0.57× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/E (TTM) 18.7× · Cheaper than median
P/B 2.41× · Pricier than median
P/S (TTM) 2.07× · Cheaper than median
P/FCF 15.0× · Cheaper than median
EV/EBITDA 11.4× · Cheaper than median
PEG 1.20× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)53 · sector 9
FUTURE (revenue growth)37 · sector 31
PAST (return on equity)47 · sector 12
HEALTH (low debt)71 · sector 97
DIVIDEND (yield)28 · sector 39

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $98.83 $74.79 −24%
Medtronic plc MDT $87.09 $65.61 −25%
Stryker Corporation SYK $278.77 $306.65 +10%
Boston Scientific Corporation BSX $43.65 $48.02 +10%
Edwards Lifesciences Corporation EW $85.19 $81.94 −4%
Siemens Healthineers AG SHL €37.86 €35.19 −7%
DexCom, Inc DXCM $86.68 $95.35 +10%
GE HealthCare Technologies Inc GEHC $66.63 $70.37 +6%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥153.86 ¥169.25 +10%
Koninklijke Philips N.V PHIA €21.87 €15.23 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Smith & Nephew plc · Fair Value
R$22.38 −19%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Smith & Nephew plc Fair Value". https://www.fairvalue-calculator.com/stock/S1NN34

Frequently asked questions

Is Smith & Nephew plc (S1NN34) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of R$22.38 versus a price of R$27.74, about −19% upside (overvalued).
What is the fair value of S1NN34?
Our model-based fair value for Smith & Nephew plc is R$22.38 (as of Sep 23, 2026), built from audited fundamentals. The current price: R$27.74.
What is the quality score of S1NN34?
Smith & Nephew plc has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Smith & Nephew plc (S1NN34)?
Our model-based price target is the fair value of R$22.38 (as of Sep 23, 2026) from 26 valuation models. Cautious scenario R$13.46, optimistic scenario R$32.80. It is a calculation from audited fundamentals, not an analyst target.
What is the Smith & Nephew plc stock forecast for 2026?
Our models put fair value at R$22.38, about −19% upside versus a price of R$27.74 (overvalued). Cautious scenario R$13.46, optimistic scenario R$32.80. The calculation is refreshed regularly with new filings.
What is the revenue of Smith & Nephew plc (S1NN34)?
Smith & Nephew plc reported trailing-twelve-month revenue of about $6.2B (latest available figure, as of Sep 23, 2026).
Does Smith & Nephew plc pay a dividend?
Smith & Nephew plc currently shows a dividend yield of about 1.41% relative to its recent price (as of Sep 23, 2026).
What growth is priced into Smith & Nephew plc (S1NN34)?
For today's price to be fair in a discounted-cash-flow model, Smith & Nephew plc would have to grow free cash flow by -3.3 % per year for five years (discount rate 11.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +4.3 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of S1NN34 use?
Our models discount Smith & Nephew plc at 11.3 %: a base by market capitalisation (large), damped by beta 0.68, country premium for Brazil. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Smith & Nephew plc that is -3.3 % per year a year over ten years, using the same discount rate (11.3 %) and the same formula as our fair value.
How much growth has Smith & Nephew plc (S1NN34) delivered so far?
Over the past 4 years revenue at Smith & Nephew plc grew +4.3 % a year. The price currently implies -3.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Smith & Nephew plc (S1NN34) growing?
The median revenue growth in the sector is +2.9 % a year. That is the yardstick for the growth priced into Smith & Nephew plc (-3.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Smith & Nephew plc (S1NN34)?
The free-cash-flow yield on the price is 18.88 %: that much free cash flow Smith & Nephew plc produces per unit of market value. When it exceeds the discount rate of our models (11.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Smith & Nephew plc (S1NN34)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Smith & Nephew plc it is R$22.38 per share (as of Sep 23, 2026), against a price of R$27.74. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Smith & Nephew plc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, S1NN34 trades above its calculated fair value: price R$27.74, fair value R$22.38, a gap of about −19% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of S1NN34?
No. The price is what the market pays today (R$27.74); the fair value is what the company's own numbers justify (R$22.38). For Smith & Nephew plc the two are R$5.36 per share apart. That gap is exactly why we show both numbers side by side.
How much is Smith & Nephew plc worth?
The market values Smith & Nephew plc at about R$66.6B (market capitalisation, as of Sep 23, 2026). Per share that is R$27.74; our models calculate a fair value of R$22.38 per share.
What do the bullish and bearish scenarios say about S1NN34?
Our models span a range for Smith & Nephew plc: cautious scenario R$13.46, base R$22.38, optimistic R$32.80 per share (as of Sep 23, 2026, price R$27.74). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of S1NN34?
Smith & Nephew plc trades at a price-to-earnings ratio of 18.7 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of R$22.38 is built from several models across several years. Other multiples: PEG 1.2, P/B 2.4, P/S 2.1, EV/EBITDA 11.4.
What is the PEG ratio of S1NN34?
The PEG ratio of Smith & Nephew plc is 1.20 (P/E divided by earnings growth, as of Sep 23, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Smith & Nephew plc (S1NN34)?
Balance-sheet figures for Smith & Nephew plc (as of Sep 23, 2026): return on equity 11.8%, debt of 0.57 per unit of equity. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
How far is S1NN34 from its 52-week high?
Smith & Nephew plc trades at R$27.74, about 26% below its 52-week high of R$37.68 and at the low of R$27.74 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of R$22.38 is for.
Which stocks are comparable to Smith & Nephew plc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Smith & Nephew plc stock attractive at the current price?
The data as of Sep 23, 2026: price R$27.74, calculated fair value R$22.38 (−19%), Quality Score 68/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of S1NN34 calculated?
We run Smith & Nephew plc through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of R$22.38, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Smith & Nephew plc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Smith & Nephew plc (S1NN34)?
The closing price on Sep 30, 2026 was R$27.74. Our model-based fair value is R$22.38, about −19% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Smith & Nephew plc right now?
Solid but not exceptional quality (68/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (R$13.46 to R$32.80) leaves room in how you read the outcome.

Key figures of Smith & Nephew plc

How large is the market capitalisation of Smith & Nephew plc (S1NN34)?
The market capitalisation of Smith & Nephew plc is R$66.6B (≈ $12.8B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Smith & Nephew plc (S1NN34)?
The price-to-sales ratio of Smith & Nephew plc is 1.90 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Smith & Nephew plc (S1NN34)?
Earnings per share at Smith & Nephew plc are R$1.48 (price ÷ EPS = P/E 18.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Smith & Nephew plc (S1NN34)?
The dividend yield of Smith & Nephew plc is 1.4% (payout 26.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Smith & Nephew plc (S1NN34)?
The net margin of Smith & Nephew plc is 10.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Smith & Nephew plc (S1NN34)?
The return on equity (ROE) of Smith & Nephew plc is 11.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Smith & Nephew plc (S1NN34)?
On an EBIT basis the return on assets of Smith & Nephew plc is 5.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Smith & Nephew plc (S1NN34)?
The operating margin of Smith & Nephew plc is 14.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Smith & Nephew plc (S1NN34)?
Revenue at Smith & Nephew plc is growing +7.4% versus a year earlier (3y avg +5.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Smith & Nephew plc (S1NN34)?
Earnings per share at Smith & Nephew plc are growing +70.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Smith & Nephew plc (S1NN34) carry?
The net debt of Smith & Nephew plc is $2.6B (fiscal year 2025, ≈ 3.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Smith & Nephew plc in the live analysis

One click puts Smith & Nephew plc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.